Updated Jul 16, 2026
Dahiyat Bassil I has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.59M.
Bassil I. Dahiyat is the President and CEO of Kodiak Sciences Inc., a biopharmaceutical company focused on developing novel therapeutics for retinal diseases. He has also held the position of Director at Xencor Inc.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | XNCR | Xencor Inc | S — Open-market sale | 6.6K | $11.02 | $73K |
| 2026-03-09 | XNCR | Xencor Inc | S — Open-market sale | 14.9K | $11.25 | $167K |
| 2026-03-05 | XNCR | Xencor Inc | S — Open-market sale | 6.8K | $11.90 | $80K |
| 2026-03-05 | XNCR | Xencor Inc | A — Grant or award | 97.3K | $0.00 | |
| 2024-11-25 | XNCR | Xencor Inc | M — Option exercise [10b5-1] | 13.5K | $15.69 | $213K |
| 2024-11-25 | XNCR | Xencor Inc | S — Open-market sale [10b5-1] | 49.3K | $24.07 | $1.19M |
| 2024-11-25 | XNCR | Xencor Inc | M — Option exercise [10b5-1] | 49.3K | $15.69 | $773K |
| 2024-11-14 | XNCR | Xencor Inc | S — Open-market sale [10b5-1] | 3.4K | $24.02 | $81K |
| 2024-11-14 | XNCR | Xencor Inc | M — Option exercise [10b5-1] | 3.4K | $15.69 | $53K |
Bassil I. Dahiyat is the President and CEO of Kodiak Sciences Inc., a biopharmaceutical company focused on developing novel therapeutics for retinal diseases. He has also held the position of Director at Xencor Inc.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($1.59M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Dahiyat Bassil I profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.